In a pooled analysis of patients treated in the VIALE-A trial and the preceding phase 1b study of azacitidine + venetoclax, there was no clear difference in outcomes of patients with FLT3-mutated AML (including both ITD and TKD) versus FLT3 wild type AML when treated with the venetoclax-based combination [13]. Here, FLT3 is linked to acute myeloid leukemia.